Main Article Content
(PR), COVID-19, PCR
Background: A new type of coronavirus family (SARS-CoV-2), that has been detected in individuals with several clinical symptoms named (COVID-19), was recognized as a pandemic on March 11, 2020. Numerous researches have been conducted on manifestations of skin disease related to COVID-19, i.e. rashes, pityriasis rosea (PR), vascular markings, and lesions as pimple-like.
Aim: This study aims to find out if the Coronavirus can affect (PR) development which also can be considered as a trigger and symptom for other types of infections.
Material and Methods: A case series descripting the dermatological finding of COVID-19 in Thi-Qar Governorate, a collective sample taking from inpatients, outpatients, the emergency unit of Al Hussein Teaching Hospital, and inwards of Al-Shefaa' Isolation Hospital. The study has been done over a four-month period (June-September, 2020.)
Results: 19 patients (10 females and 9 males), who have infected with Coronavirus and were suffering from (PR), are included in this study. The highest percentage of females 52.6% and males 47.4%. The distribution of patients according to the incidence of (PR) in typical and anomalous manners had the percentage of typical 77.9% and abnormal 21.1%. The highest percentage was in moderate Covid-19 (84.2%), while it was 15.8% in mild Covid-19. There was no significant statistical difference in mean age distribution according to gender while there were significant statistical differences according to (PR) and COVID-19 class. More studies are needed to evaluate whether or not these lesions are associated with the virus.
Conclusion: The (PR) was one of the dermatological finding of COVID-19, that did not have a clear role in the distribution of the disease according to the background of the patients and also the severity of COVID-19. It can be triggered by COVID-19 and completely cured with the clearance of the disease.
Recommendation: An accurate robust cutaneous documentation related to Covid19 is required to increase the knowledge of disease as well as its epidemiology.
 C. G. Casas et al., “Classification of the cutaneous manifestations of COVID-19 : a rapid prospective nationwide consensus study in Spain with 375 cases,” Br. J. Dermatol., vol. 183, no. 6, pp. 71–77, 2020.
 I. Torres-Navarro, C. Abril-Perez, J. Roca-Gines, J. Sanchez-Arraez, and R. Botella-Estrada, “Erythema multiforme and Kawasaki disease associated with COVID-19 infection in children,” Eur. Acad. Dermatology Venereol., vol. 34, no. 6, pp. 539–541, 2020.
 K. Mahajan, V. Relhan, A. K. Relhan, and V. K. Garg, “(PR) : An Update on Etiopathogenesis and Management of Difficult Aspects,” Indian J. Dermatol., vol. 61, no. 4, pp. 375–384, 2016.
 A. A. T. Chuh and V. Zawar, “(PR) ,” Harper’s Textb. Pediatr. Dermatology, vol. 34, no. 6, pp. 416–421, 2020.
 V. Zawar, H. Jerajani, and R. Pol, “Current trends in (PR) ,” Expert Rev. Dermatol, vol. 5, no. 3, pp. 325–333, 2010.
 R. Balestri, G. Rech, and C. R. Girardelli, “(PR) as a cutaneous manifestation of COVID-19 infection,” Eur. Acad. Dermatology Venereol., vol. 34, no. 7, pp. 436–437, 2020.
 U. Wollina, A. S. Karada!, and C. Rowland-Payne, “Cutaneous signs in COVID-19 patients : A review,” Dermatol. Ther., vol. 6, no. 5, pp. 1–6, 2020.
 G. Stinco, M. Ruscio, D. Proscia, and F. Piccirillo, “Borrelia Infection and (PR) ,” Acta Derm Venereol, vol. 89, no. 6, pp. 97–98, 2008.
 S. A. Temiz et al., “Evaluation Of DermatologyConsultationsInTheEra Of COVID19,” Orig. Artic., vol. 6, no. 7, pp. 1–10, 2020.
 M. YUKSEL, “(PR) Recurrence is Much Higher than Previously Known :A Prospective Study,” Investig. Rep., vol. 99, no. 9, pp. 664–667, 2019.
 S. T. S. Hassan, “Shedding Light on the Effect of Natural Anti-Herpesvirus Alkaloids on SARS-CoV-2: A Treatment Option for COVID-19,” Viruses 2020, vol. 476, no. 12, pp. 12–15, 2020.
 C. S. Gonçalves et al., “Erythematous Papular Rash: A Dermatological Feature of COVID-19 Catarina,” Eur. J. Case Reports Intern. Med., vol. 5, no. 5, pp. 56–58, 2020.
 D. M. Enguix, M. del C. S. Nievas, and D. T. M. Romeroc, “(PR) Gibert type rash in an asymptomatic patient that tested positive for COVID-19,” vol. 155, no. 6, p. 273, 2020.
 P. Suchonwanit, “Diagnostic and prognostic values of cutaneous manifestations in COVID-19,” Dermatologic Therapy, no. 5. pp. 10–11, 2020.
 Ö. Kutlu and A. Metin, “Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of the COVID-19 pandemic,” Dermatol. Ther., vol. 8, no. 7, pp. 1–5, 2020.
 G. Daneshgaran, D. P. Dubin, and D. J. Gould, “Cutaneous Manifestations of COVID ‑ 19 : An Evidence ‑ Based Review,” Am. J. Clin. Dermatol., vol. 21, no. 5, pp. 627–639, 2020.
 A. Català et al., “Maculopapular eruptions associated to COVID-19 : A subanalysis of the COVID-Piel study,” Dermatologic Ther., vol. 26, no. 6, pp. 1–10, 2020.
 S. Shaukat, G. Butt, and I. Hussain, “Cutaneous manifestations of COVID-19,” J. Pakistan Assoc. Dermatologists, vol. 30, no. 1, pp. 181–189, 2020.
 S. L. Mawhirt, D. Frankel, and A. M. Diaz, “Cutaneous Manifestations in Adult Patients with COVID-19 and Dermatologic Conditions Related to the COVID-19 Pandemic in Health Care Workers,” Curr. Allergy Asthma Rep., vol. 12, no. 10, pp. 1–13, 2020.
 Ç. Turan, N. Metin, Ö. S. Kotan, UtlumZeynep, and Ö. Ümran, “Change of the diagnostic distribution in applicants to dermatology after COVID-19 pandemic : What it whispers to us ?,” Dermatol. Ther., vol. 4, no. 6, pp. 1–9, 2020.
 Tahmasebi, Safa, et al. "The effects of oxygen–ozone therapy on regulatory T‐cell responses in multiple sclerosis patients." Cell biology international (2021).
 D. Lipsker, “Paraviral eruptions in the era of COVID-19 : Do some skin manifestations point to a natural resistance to SARS-CoV-2 ?,” Clin. Dermatol., vol. 6, no. 7, pp. 1–5, 2020.
 Shabgah, Arezoo Gowhari, et al. "CXC chemokine ligand 16: a Swiss army knife chemokine in cancer." Expert Reviews in Molecular Medicine 23 (2021).